Focused On-demand Library for Centriole and centriolar satellite protein OFD1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O75665

UPID:

OFD1_HUMAN

Alternative names:

Oral-facial-digital syndrome 1 protein; Protein 71-7A

Alternative UPACC:

O75665; B9ZVU5; O75666; Q4VAK4

Background:

Centriole and centriolar satellite protein OFD1, also known as Oral-facial-digital syndrome 1 protein, plays a crucial role in centriole length control and ciliogenesis. It recruits essential proteins like IFT88 and CEP164 to centrioles, facilitating cilium biogenesis, a process vital for cell signaling and tissue homeostasis. OFD1's involvement in Wnt signaling and left-right axis specification underscores its significance in development.

Therapeutic significance:

OFD1's mutation is linked to diseases such as Orofaciodigital syndrome 1, Simpson-Golabi-Behmel syndrome 2, Joubert syndrome 10, and Retinitis pigmentosa 23. Understanding OFD1's role could pave the way for innovative treatments targeting these genetic disorders, highlighting the protein's therapeutic potential.